Table 1.
Characteristics of the patients at baseline
| SZC (N = 92) | Placebo (N = 90) | ||
|---|---|---|---|
| Age (years) | Mean ± SD | 72.9 ± 8.8 | 71.0 ± 8.1 |
| Sex n (%) | Male | 51 (55.4) | 57 (63.3) |
| Race n (%) | White | 90 (97.8) | 89 (98.9) |
| Body‐mass index (kg/m2) | Mean ± SD | 29.6 ± 5.6 | 30.2 ± 5.6 |
| NYHA class n (%) | II | 61 (66.3) | 57 (63.3) |
| III | 31 (33.7) | 33 (36.7) | |
| LV ejection fraction (%) | Mean ± SD | 33.8 ± 5.8 | 33.9 ± 6.1 |
| NT‐proBNP (pmol/L) | Mean ± SD | 319.4 ± 428.3 | 288.5 ± 399.6 |
| Potassium (mmol/L)a | Mean ± SD | 4.85 ± 0.37 | 4.87 ± 0.33 |
| Potassium group (mmol/L)a | ≤5.0 | 65 (70.7) | 67 (74.4) |
| >5.0 | 27 (29.3) | 23 (25.6) | |
| eGFR (mL/min/1.73 m2)b | Mean ± SD | 40.0 ± 11.0 | 42.7 ± 11.5 |
| eGFR group (mL/min/1.73 m2)b | ≤20 | 2 (2.2) | 1 (1.1) |
| >20–≤45 | 60 (65.2) | 53 (58.9) | |
| >45–<60 | 26 (28.3) | 31 (34.4) | |
| ≥60 | 4 (4.3) | 5 (5.6) | |
| Diabetes mellitus n (%) | 40 (43.5) | 42 (46.7) | |
| Atrial fibrillation n (%) | 42 (45.7) | 42 (46.7) | |
| Hypertension n (%) | 86 (93.5) | 85 (94.4) | |
| ACE inhibitor n (%) | 43 (46.7) | 45 (50.0) | |
| Angiotensin II receptor blocker n (%) | 34 (37.0) | 28 (31.1) | |
| Sacubitril‐valsartan n (%) | 14 (15.2) | 16 (17.8) | |
| Mineralocorticoid antagonist n (%) | 16 (17.4) | 18 (20.0) | |
| Diuretic n (%) | 78 (84.8) | 77 (85.6) | |
| Beta‐blocker n (%) | 83 (90.2) | 83 (92.2) | |
Abbreviations: ACE, angiotensin‐converting enzyme; eGFR, estimated glomerular filtration rate; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide; NYHA, New York Heart Association.